No title
New alternatives for treatment of overactive bladder (OAB) syndrome are continuously being explored. Despite ongoing nonclinical and clinical research, few new principles have evolved. We can expect future new additions to existing drug classes and different combinations of existing options. New antimuscarinics are in development, but we do not know if they offer any advantages to currently availa
